TraitHigh for current CPIC guidance
Skin-reaction risk and dose planning for phenytoin and fosphenytoin
Skin-reaction risk and dose planning for phenytoin and fosphenytoin is a genetic trait Biome reports in its medication response panel: HLA-B and CYP2C9 results can help a clinician check serious skin-reaction risk and plan ongoing doses of the seizure medicines phenytoin and fosphenytoin.
- Category
- Medication response
- Markers
- HLA-B*15:02 and CYP2C9 diplotype/activity score
- Strength of evidence
- High for current CPIC guidance
- DNA-test coverage
- Stronger with whole genome
Genes
How Biome reads this
Biome's whole-genome test reads this from one saliva sample, alongside all 3.2 billion letters of your DNA.
Biome DNA test →This page is for educational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Genetic results describe tendencies and predispositions, not diagnoses. Always consult a licensed clinician before making decisions about your health, medications, or supplements.